Last reviewed · How we verify
Cytoflavin® enteric-coated tablet — Competitive Intelligence Brief
phase 3
Metabolic enhancer / Antioxidant combination
Neurology / Metabolic disorders
Small molecule
Live · refreshed every 30 min
Target snapshot
Cytoflavin® enteric-coated tablet (Cytoflavin® enteric-coated tablet) — POLYSAN Scientific & Technological Pharmaceutical Company. Cytoflavin is a combination drug that enhances cellular energy metabolism and reduces oxidative stress through its active components.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cytoflavin® enteric-coated tablet TARGET | Cytoflavin® enteric-coated tablet | POLYSAN Scientific & Technological Pharmaceutical Company | phase 3 | Metabolic enhancer / Antioxidant combination |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Metabolic enhancer / Antioxidant combination class)
- POLYSAN Scientific & Technological Pharmaceutical Company · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cytoflavin® enteric-coated tablet CI watch — RSS
- Cytoflavin® enteric-coated tablet CI watch — Atom
- Cytoflavin® enteric-coated tablet CI watch — JSON
- Cytoflavin® enteric-coated tablet alone — RSS
- Whole Metabolic enhancer / Antioxidant combination class — RSS
Cite this brief
Drug Landscape (2026). Cytoflavin® enteric-coated tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/cytoflavin-enteric-coated-tablet. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing